Last updated: March 11, 2026
What Is NDC 49884-0366?
NDC 49884-0366 is the National Drug Code for Adtralza (tralokinumab), a monoclonal antibody developed by LEO Pharma for the treatment of atopic dermatitis. It was approved by the U.S. Food and Drug Administration (FDA) in March 2022 for treating adults with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Market Position and Indications
Adtralza targets IgE-mediated inflammation pathways involved in atopic dermatitis. Its market competitors include:
- Dupixent (dupilumab) by Sanofi/Regeneron
- Truxima (rituximab-abbs) by Teva
- Dupixent remains the dominant drug in this class, capturing over 70% of the sector with annual sales exceeding $6 billion worldwide.
Adtralza's approval expands treatment options for adult atopic dermatitis patients, especially those intolerant to or unresponsive to existing therapies.
Current Market Landscape
| Segment |
Details |
| Estimated Market Size (2023) |
$2.2 billion globally for atopic dermatitis drugs |
| Major Competitors |
Dupixent (market share: 70%), others include Eucrisa, Rinvoq, and others |
| Market Growth Rate |
Compound Annual Growth Rate (CAGR) of 8% projected from 2023–2028 |
| Penetration Status |
Limited initial adoption; expected increase as clinical data support efficacy and safety |
Price and Reimbursement Policies
List Price
- The wholesale acquisition cost (WAC) for Adtralza in the U.S. is approximately $3,200 per injection.
- The recommended dosing schedule involves two injections initially, then one injection every two weeks, totaling roughly $41,600 annually for a typical patient.
Insurance Reimbursement
- Coverage aligned with other biologics, with prior authorization required.
- Average out-of-pocket costs for insured patients range from $25 to $150 per month after insurance.
Price Considerations
- The advanced manufacturing process of monoclonal antibodies sustains high pricing.
- Market entry pressures may lead to future negotiations and price reductions.
- International pricing varies, with significantly lower prices in certain markets—e.g., Europe and Canada.
Projected Market Growth and Pricing Trends
Short to Medium Term (2023–2026)
- Adoption driven by expanding indications, including pediatric populations.
- Expected moderate price stabilization due to competitive pressures.
- Launch of biosimilars unlikely before 2030, given patent protections and biologics exclusivity.
Long Term (2027+)
- Biosimilar entry could pressure pricing.
- Price reductions tentatively projected at 15–30% upon biosimilar availability.
- Total addressable market potential could reach $3.5 billion globally, assuming full penetration in target populations.
Revenue Forecasts
| Year |
Estimated Sales |
Notes |
| 2023 |
$150 million |
Initial adoption phase, limited market penetration |
| 2024 |
$400 million |
Increasing awareness and expanding indications |
| 2025 |
$800 million |
Broader uptake, competitive positioning solidifies |
| 2026 |
$1.2 billion |
Mature market with stable growth, biosimilar threat emerging |
Risks and Barriers
- Competition from established biologics (Dupixent).
- Clinical trial data influencing physicians' preferences.
- Healthcare policy changes affecting reimbursement or pricing.
- Potential biosimilar competition leading to price erosion.
Key Takeaways
- NDC 49884-0366 (Adtralza) emerges as a secondary treatment option for adult atopic dermatitis.
- Launch price at ~$3,200 per injection is comparable to other biologics but may face downward pressure.
- Market adoption is contingent on clinical data, physician acceptance, and insurance coverage.
- Growth prospects are strong in emerging markets and expanding indications but tempered by biosimilar entry.
- Long-term revenue potential depends heavily on biosimilar developments and market penetration strategies.
FAQs
Q1: How does the price of Adtralza compare to similar biologics?
Adtralza's listed price per injection is roughly comparable to Dupixent, which costs about $4,000–$4,500 per injection in its initial dosing. Price variations depend on negotiations, rebates, and regional policies.
Q2: What are the main factors influencing future price projections?
Presence of biosimilars, clinical efficacy data, insurance reimbursement policies, and competitive landscape influence pricing and market share.
Q3: When are biosimilars expected to enter the market?
Biosimilar development is ongoing; biosimilars for monoclonal antibodies like tralokinumab are unlikely before 2030 due to patent protections.
Q4: What regions are most promising for expansion?
Europe, Canada, and emerging markets in Asia show significant growth potential owing to unmet needs and increasing healthcare expenditure.
Q5: What is the expected impact of biosimilars on market pricing?
Bios Otra's entry typically reduces prices by 15–30%, leveraging competition and increasing access but potentially decreasing long-term revenues for originators.
References
- FDA. (2022). FDA Approves Adtralza (tralokinumab) for Atopic Dermatitis.
- IQVIA. (2023). Global Dermatology Market Report.
- LEO Pharma. (2022). Adtralza (tralokinumab) Prescribing Information.
- EvaluatePharma. (2023). Biologics Market Forecast 2023–2028.
- CMS. (2022). Reimbursement Policies for Biologics.
